Summary & Overview
CPT 79440: Radiopharmaceutical Joint Injection for Synovial Inflammation
CPT code 79440 denotes intra-articular injection of a radioactive agent (radiosynoviorthesis) to treat synovial inflammation. This targeted therapeutic procedure is used in rheumatologic and orthopedic care to reduce pain and inflammation inside affected joints when other conservative treatments are insufficient. Nationally, the code matters for payers and providers because it represents a specialized, procedure-based therapy with implications for site-of-service designation, prior authorization, and coverage policy.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the procedure, typical sites of service, common modifiers used in billing, and the payer landscape considered in this analysis. The publication outlines benchmarks and reimbursement considerations, summarizes relevant policy updates impacting coverage and utilization management, and clarifies coding implications for procedural documentation and claims submission.
This summary is intended for billing managers, revenue cycle professionals, and clinicians involved in procedural care planning who need a concise reference to the clinical intent and payer relevance of CPT code 79440 at a national level.
Billing Code Overview
CPT code 79440 describes a procedure in which a provider injects a radioactive substance into a joint to reduce synovial inflammation. This is a targeted therapeutic injection using radiopharmaceuticals intended to alleviate inflammatory symptoms within the joint space.
-
Service type: Image-guided or intra-articular radiopharmaceutical joint injection
-
Typical site of service: Outpatient procedural setting such as an ambulatory surgical center, hospital outpatient department, or specialized imaging/interventional clinic
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with chronic, refractory synovitis of the knee secondary to osteoarthritis presents after failing conservative measures including oral/IA corticosteroids and hyaluronic acid injections. The orthopedic or rheumatology team evaluates the patient, confirms ongoing inflammatory joint pain with synovial hypertrophy on ultrasound or MRI, and discusses radiosynoviorthesis as a therapeutic option. On the day of service the patient is verified for allergies and anticoagulation status, informed consent is obtained, and baseline vitals are recorded. Under sterile technique in an outpatient procedure suite or hospital outpatient department, the provider aspirates joint effusion if present, injects a radiopharmaceutical (commonly yttrium-90, rhenium-186, or erbium-169 depending on joint size) into the joint space, and may administer a small local anesthetic. Post-injection the limb is immobilized for a short period and radiation safety instructions are given. Typical follow-up includes activity restrictions for 48–72 hours, symptom reassessment at 4–8 weeks, and imaging if clinically indicated. Typical sites of service are outpatient procedure suite, ambulatory surgical center, or hospital outpatient department. Providers commonly performing this procedure include rheumatologists, orthopedic surgeons, and nuclear medicine physicians.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Request for additional reimbursement when service is the usual, regular, and necessary level of care | Use when this procedure is the primary service and performed in the usual manner without complications |